Reyvow

Chemical Namelasmiditan
Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassReceptor agonists
SystemNervous
CompanyEli Lilly and Company
Approval Year2020

Indication

  • Reyvow is indicated for the acute treatment of migraine with or without aura in adults.
Last updated on 2/2/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Reyvow (lasmiditan) Prescribing Information 2020Eli Lilly And Co
Document TitleYearSource
Lasmiditan for the acute treatment of migraine. 2020CADTH